Clinical Trial Update: Efficacy of Liposomal Bupivacaine for Pain Control After Percutaneous Nephrostolithotomy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating liposomal bupivacaine for postoperative pain control after percutaneous nephrostolithotomy was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Calculi

Drugs mentioned

• Exparel (liposomal bupivacaine)

Snippet

Sponsor: Northwell Health | Conditions: Renal Calculi, Postoperative Pain | Phase 3 | Status: WITHDRAWN